436.00
price up icon0.45%   1.97
after-market Handel nachbörslich: 435.00 -1.00 -0.23%
loading
Schlusskurs vom Vortag:
$434.03
Offen:
$428.68
24-Stunden-Volumen:
1.43M
Relative Volume:
0.86
Marktkapitalisierung:
$111.96B
Einnahmen:
$11.10B
Nettoeinkommen (Verlust:
$-988.90M
KGV:
-111.22
EPS:
-3.92
Netto-Cashflow:
$-1.26B
1W Leistung:
-0.60%
1M Leistung:
-11.46%
6M Leistung:
-3.32%
1J Leistung:
-3.28%
1-Tages-Spanne:
Value
$427.43
$436.59
1-Wochen-Bereich:
Value
$427.43
$448.00
52-Wochen-Spanne:
Value
$377.85
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Firmenname
Vertex Pharmaceuticals Inc
Name
Telefon
(617) 341-6393
Name
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Name
Mitarbeiter
6,100
Name
Twitter
@VertexPharma
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
VRTX's Discussions on Twitter

Vergleichen Sie VRTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 112.64B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 27.03B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 40.86M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 64.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 6.07B 0 -153.72M -103.81M -2.00

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-07 Herabstufung Wolfe Research Outperform → Peer Perform
2025-05-06 Herabstufung Leerink Partners Outperform → Market Perform
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-02-12 Hochstufung Canaccord Genuity Sell → Hold
2025-02-11 Hochstufung Canaccord Genuity Sell → Hold
2025-01-30 Herabstufung Wells Fargo Overweight → Equal Weight
2024-12-20 Bestätigt H.C. Wainwright Buy
2024-12-19 Herabstufung Oppenheimer Outperform → Perform
2024-12-09 Hochstufung Jefferies Hold → Buy
2024-11-14 Eingeleitet Citigroup Buy
2024-10-16 Eingeleitet Scotiabank Sector Perform
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-08-05 Herabstufung Barclays Overweight → Equal Weight
2024-06-27 Eingeleitet Redburn Atlantic Buy
2024-04-11 Hochstufung Evercore ISI In-line → Outperform
2024-02-15 Eingeleitet Wolfe Research Outperform
2024-02-06 Herabstufung Evercore ISI Outperform → In-line
2024-02-02 Herabstufung Bernstein Outperform → Mkt Perform
2024-01-31 Herabstufung Maxim Group Buy → Hold
2024-01-31 Herabstufung Robert W. Baird Neutral → Underperform
2024-01-24 Herabstufung Canaccord Genuity Hold → Sell
2023-12-14 Bestätigt RBC Capital Mkts Sector Perform
2023-05-30 Eingeleitet William Blair Outperform
2023-05-04 Fortgesetzt Piper Sandler Overweight
2023-03-21 Eingeleitet Bernstein Outperform
2023-01-18 Eingeleitet Canaccord Genuity Hold
2023-01-17 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-12-19 Herabstufung Jefferies Buy → Hold
2022-07-13 Eingeleitet Cantor Fitzgerald Overweight
2022-06-01 Hochstufung Maxim Group Hold → Buy
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-05-06 Herabstufung Robert W. Baird Outperform → Neutral
2022-05-03 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-02-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-01-27 Bestätigt JP Morgan Overweight
2022-01-27 Bestätigt Morgan Stanley Underweight
2022-01-27 Bestätigt RBC Capital Mkts Outperform
2022-01-27 Bestätigt Stifel Hold
2022-01-27 Bestätigt Wolfe Research Outperform
2022-01-20 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-12-09 Eingeleitet Wells Fargo Overweight
2021-11-19 Eingeleitet BMO Capital Markets Market Perform
2021-11-19 Herabstufung Piper Sandler Overweight → Neutral
2021-09-09 Herabstufung Stifel Buy → Hold
2021-09-07 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-07-20 Herabstufung SVB Leerink Mkt Perform → Underperform
2021-07-19 Fortgesetzt Wolfe Research Outperform
2021-07-01 Eingeleitet Raymond James Mkt Perform
2021-06-11 Herabstufung Daiwa Securities Outperform → Neutral
2021-02-23 Hochstufung Robert W. Baird Neutral → Outperform
2021-02-02 Bestätigt H.C. Wainwright Buy
2020-12-30 Eingeleitet Daiwa Securities Outperform
2020-11-30 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2020-11-20 Eingeleitet Bernstein Outperform
2020-10-28 Eingeleitet UBS Buy
2020-07-31 Bestätigt H.C. Wainwright Buy
2020-07-08 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-04-30 Bestätigt H.C. Wainwright Buy
2020-04-28 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-03-04 Eingeleitet Barclays Overweight
2020-01-31 Herabstufung Robert W. Baird Outperform → Neutral
2019-11-19 Hochstufung Guggenheim Neutral → Buy
2019-11-12 Eingeleitet SunTrust Buy
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-09-03 Hochstufung Goldman Neutral → Buy
2019-08-01 Herabstufung Needham Buy → Hold
2019-05-23 Fortgesetzt Citigroup Buy
2019-05-21 Eingeleitet Credit Suisse Outperform
2019-04-12 Eingeleitet Evercore ISI In-line
2019-03-26 Hochstufung William Blair Mkt Perform → Outperform
2019-03-19 Herabstufung SVB Leerink Outperform → Mkt Perform
2019-02-06 Herabstufung Maxim Group Buy → Hold
Alle ansehen

Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten

pulisher
May 24, 2025

2 Monster Growth Stocks to Buy and Hold for 10 Years - The Motley Fool

May 24, 2025
pulisher
May 23, 2025

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? (NASDAQ:VRTX) - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Vertex Pharmaceuticals (VRTX) Downgraded Due to High Inventory Levels | VRTX Stock News - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Vertex Pharmaceuticals (VRTX) Announces $4 Billion Share Buyback Program - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN

May 22, 2025
pulisher
May 21, 2025

Vertex Pharma announces new share buybacks worth up to $4B - MSN

May 21, 2025
pulisher
May 21, 2025

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish? - MSN

May 21, 2025
pulisher
May 21, 2025

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart.com

May 21, 2025
pulisher
May 21, 2025

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - Yahoo Finance

May 21, 2025
pulisher
May 20, 2025

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years - Benzinga

May 20, 2025
pulisher
May 20, 2025

Vertex Pharma stock gains on share buybacks (VRTX:NASDAQ) - Seeking Alpha

May 20, 2025
pulisher
May 19, 2025

Vertex Pharmaceuticals (VRTX) Announces New $4 Billion Stock Rep - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Vertex Pharmaceuticals Authorizes $4 Billion In Additional Share Repurchases - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

August 15th Options Now Available For Vertex Pharmaceuticals (VRTX) - Nasdaq

May 19, 2025
pulisher
May 19, 2025

VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss - Yahoo Finance

May 19, 2025
pulisher
May 15, 2025

Vertex to Participate in Upcoming Investor Conferences | VRTX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Vertex to Participate in Upcoming Investor Conferences - Business Wire

May 15, 2025
pulisher
May 14, 2025

Vertex Pharmaceuticals Holds Annual Shareholder Meeting - TipRanks

May 14, 2025
pulisher
May 14, 2025

Stifel maintains hold on Vertex stock with $494 target - Investing.com

May 14, 2025
pulisher
May 13, 2025

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga

May 13, 2025
pulisher
May 13, 2025

Best Biotech Stocks to Buy in 2025 - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Fund Update: TRILLIUM ASSET MANAGEMENT, LLC added 38,854 shares of VERTEX PHARMACEUTICALS ($VRTX) to their portfolio - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Our future journey in cystic fibrosis - Vertex Pharmaceuticals

May 12, 2025
pulisher
May 11, 2025

Vertex says late-stage studies of VX-659 triple combination therapy in CF hit main goals - FirstWord Pharma

May 11, 2025
pulisher
May 11, 2025

ViewPoints: Vertex settles on a dynastic successor - FirstWord Pharma

May 11, 2025
pulisher
May 11, 2025

Vertex's VX-445 triple combination regimen achieves main goals of two late-stage studies in CF - FirstWord Pharma

May 11, 2025
pulisher
May 11, 2025

Vertex moves forward with regulatory filings after selecting VX-445 for triple-combination regimen in CF - FirstWord Pharma

May 11, 2025
pulisher
May 11, 2025

Is Vertex Pharmaceuticals (VRTX) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey

May 11, 2025
pulisher
May 11, 2025

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga

May 11, 2025
pulisher
May 10, 2025

VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - MSN

May 10, 2025
pulisher
May 09, 2025

Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft - CNBC

May 09, 2025
pulisher
May 09, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks - MSN

May 09, 2025
pulisher
May 08, 2025

Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - MSN

May 08, 2025
pulisher
May 08, 2025

Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025
pulisher
May 07, 2025

Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug - MSN

May 07, 2025
pulisher
May 07, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals (XTRA:VX1) - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Vertex Pharmaceuticals (VRTX) Faces Downgrade After Q1 Revenue Miss - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Vertex Pharma stock downgraded at Wolfe (VRTX:NASDAQ) - Seeking Alpha

May 07, 2025
pulisher
May 07, 2025

Cystic fibrosis Market: Epidemiology, Therapies, Companies, - openPR.com

May 07, 2025
pulisher
May 07, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals (BIT:1VRTX) - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Vertex Pharmaceuticals (VRTX) Sees Target Price Increase to $499 by Barclays | VRTX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com

May 07, 2025
pulisher
May 07, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals (WBAG:VRTX) - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Vertex Pharmaceuticals (VRTX) Downgraded Amid Revenue Concerns | VRTX Stock News - GuruFocus

May 07, 2025

Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.335
price up icon 6.39%
$588.34
price down icon 1.43%
$75.06
price up icon 3.26%
$4.25
price up icon 0.48%
$289.96
price up icon 0.33%
Kapitalisierung:     |  Volumen (24h):